Torrent Pharmaceuticals Ltd Share Price – NSE  / BSE

Pharmaceuticals, Mid Cap

Torrent Pharma has approved the issuance of Secured, Rated, Listed, Redeemable Non-Convertible Debentures (NCDs) aggregating upto Rs 12,500 crore in one or more tranches on private placement basis.

Powered by Capital Market - Live News

Torrent Pharmaceuticals said India Ratings and Research has reaffirmed the credit rating of the company?s existing banking facilities, issuer rating and non-convertible debentures at IND AA+ with a stable outlook.

The rating agency has also assigned a short-term rating of IND A1+ to Torrent Pharma's proposed commercial paper programme, indicating a strong degree of safety with respect to timely servicing of financial obligations.

The company's securities transfer and stakeholders relationship committee will meet on 5 January 2026 to consider the issuance of secured non-convertible debentures through a private placement, within the borrowing limits already approved by the board in July 2025.

Torrent Pharma is the flagship company of the Torrent Group. It is ranked 7th in the Indian Pharmaceuticals Market and is amongst the Top 5 in the therapeutics segments of Cardiovascular (CV), Gastro Intestinal (GI), Central Nervous System (CNS) and Cosmo-Dermatology. It is a specialty-focused company with ~76% of its revenues in India from chronic & sub-chronic therapies. It has presence in 50+ countries and is ranked No. 1 amongst the Indian pharma companies in Brazil and Germany. Torrent has 8 manufacturing facilities, of which 5 are USFDA approved.

On a consolidated basis, the company's net profit rose 30.46% to Rs 591 crore while net sales rose 14.66% to Rs 3246 crore in Q2 September 2025 over Q2 September 2024.

Shares of Torrent Pharmaceuticals rose 0.96% to settle at Rs 3884.85 on Friday, 2 January 2026.

Powered by Capital Market - Live News

The proposed issuance will be within the limits already approved by the company?s Board of Directors at its meeting held on 28 July 2025, the company said in an exchange filing.

Torrent Pharma is the flagship company of the Torrent Group. It is ranked 7th in the Indian Pharmaceuticals Market and is amongst the Top 5 in the therapeutics segments of Cardiovascular (CV), Gastro Intestinal (GI), Central Nervous System (CNS) and Cosmo-Dermatology. It is a specialty-focused company with ~76% of its revenues in India from chronic & sub-chronic therapies. It has presence in 50+ countries and is ranked No. 1 amongst the Indian pharma companies in Brazil and Germany. Torrent has 8 manufacturing facilities, of which 5 are USFDA approved.

On a consolidated basis, its revenue rose 14% year-on-year to Rs 3,302 crore, compared to Rs 2,889 crore in Q2 FY25. Gross profit stood at Rs 2,502 crore, up 13% YoY, maintaining a healthy margin of 76%.

The counter shed 0.34% to Rs 3,807.60 on the BSE.

Powered by Capital Market - Live News

Torrent Pharmaceuticals will hold a meeting of the Board of Directors of the Company on 5 January 2026.

Powered by Capital Market - Live News